Agilent Technologies, Inc. (A) - Stock Analysis

Last updated: Aug 15, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Agilent reported 6.3% organic growth, results above guidance, margin expansion, and higher fiscal 2026 growth and EPS guidance. Shares gained 14.6% through August 19, with fiscal Q3 earnings due August 26.

Loading chart data...

Idea window: 8/19/2026 – 8/26/2026Sector: Healthcare

AI Analyst Overview

Last Price
$155.94
Market Cap
$43.89B
1D Return
+0.34%
YTD Return
+15.29%

Loading chart data...

Valuation Metrics

P/E
31.1
P/B
6.2
P/S
6.1
EV/EBITDA
24.1
Div Yield
0.65%

Fundamental Analysis

8.5

Key Financial Insights: • Profitability Strength • Strong Cash Flow • Premium Valuation A is a highly profitable, cash-generative business with improving liquidity and leverage, but its premium valuation and intangibles-heavy balance sheet limit downside protection.

profitable
expensive

Price Behavior

6.5

Key Price Behavior Insights: • Higher lows • Support holding • Near resistance Support Level: $140-$141 Resistance Level: $149.5 Over the last month, A has trended higher with a series of higher lows and support building around $140-$141, but it is now stretched near $149.5 and vulnerable to a short-term pause unless it breaks resistance.

uptrend
overbought

Sentiment & News

6.5

Key News Insights: • EU certification • PFAS research • Investor interest Agilent's latest updates point to steady momentum in diagnostics and research, led by EU certification for its PD-L1 companion diagnostic, a strategic X-ray tech investment, PFAS research support, and rising investor attention ahead of Q3 results.

Agilent
Diagnostics
AI

AI Summary

6.5
Positive

A has re-rated from a defensive lab-tools name into a higher-quality compounder with improving margins, strong FCF, and new diagnostics/regulatory tailwinds, but at ~30x earnings the stock now needs continued execution—especially in China and cash conversion—to justify further upside rather than risk multiple compression.

QualityCompounding
Valuation
Execution
AI summary updated 4 days ago

Description

Agilent Technologies supplies instruments, consumables and software for life sciences, diagnostics and applied chemical laboratories worldwide. Its offerings span analytical instrumentation (chromatography, mass spectrometry, spectroscopy), cell and molecular biology platforms, genomic assays and laboratory automation, while a dedicated services unit provides columns, consumables, software and operational support. The company sells through direct and indirect channels and is headquartered in Santa Clara, California, incorporated in 1999.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Aug 19Aug 26AAgilent Technologies, Inc.
Agilent reported 6.3% organic growth, results above guidance, margin expansion, and higher fiscal 2026 growth and EPS guidance. Shares gained 14.6% through August 19, with fiscal Q3 earnings due August 26.
Active+0.9%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.